Open for inclusion

Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT

Cancer type: Myeloma

Phase: II

Principal Investigator: Schjesvold Fredrik

Country: NO

Keywords: Norway, Oslo

Status: Open for inclusion

Link to